Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05874674

The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study

Comparison nafamostat and low molecular weight heparin among dialysis patients

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Dialysis; Complications Bleeding Hemorrhage Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Yonsei Unviersity Wonju College of Medicin

Wŏnju, Kangwondo, 26426, South Korea

Location status: Recruiting

Location contact

Jun Young Lee

CONTACT

[email protected]

820337410935

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • platelet below 10k PTT above 60 second INR above 20 patient with bleeding (epistaxis, orbital bleeding, hematuria) recent brain hemorrhage (within 6 months) receiving anticoagulant therapy (coumadin or NOAC) dual antiplatelet agent users received major surgery within one month

Exclusion criteria

  • cancer liver cirrhosis pregnancy drug allergy current bleeding on major organ (brain, gastrointestinal)

Treatment and study plan

Nafamostat Mesylate

Drug

Comparison effect of nafamostat and cnoxan

Other names: cnoxan

Primary outcomes

  1. Number of patients with severe bleeding

    Time frame: 6 month

    Brain hemorrhage (on brain CT), gastrointestinal bleeding (on EGD)

Secondary outcomes

  1. Number of patients with dialysis circuit clot

    Time frame: 6 month

    Dialysis circuit clotting due to not enough anticoagulation

Sponsors and collaborators

Lead sponsor

Wonju Severance Christian Hospital

Other

Registry information

Official study title

The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Diathesis Undergoing Hemodialysis: A Pilot Study

Acronym: Nafamostat

Important dates

Study start
2023
Primary completion
2025
Study completion
2026
First posted
May 25, 2023
Registry last updated
Jul 30, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.